Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,206,854 papers from all fields of science
Search
Sign In
Create Free Account
FTY-720
Known as:
FTY 720
, FTY720
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (2)
fingolimod
fingolimod hydrochloride
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2008
Highly Cited
2008
FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves
Zhiren Zhang
,
Zhi-Yuan Zhang
,
U. Fauser
,
H. Schluesener
Experimental Neurology
2008
Corpus ID: 207687923
Review
2007
Review
2007
FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis
T. Baumruker
,
A. Billich
,
V. Brinkmann
Expert Opinion on Investigational Drugs
2007
Corpus ID: 23289454
FTY720 (fingolimod; 2-amino-2[2-(4-octylphenyl)ethyl]-1,3-propanediol, Novartis) is the prototype of a new generation of…
Expand
Highly Cited
2004
Highly Cited
2004
FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation.
T. Lee
,
K. Man
,
+7 authors
S. Fan
Carcinogenesis
2004
Corpus ID: 35567101
Our aim was to study the anticancer effect of the novel immunomodulator FTY720 in vitro and in vivo by investigation of cell…
Expand
Highly Cited
2002
Highly Cited
2002
Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: Modulation of mitogenic signaling, FAK, cell‐cycle entry and apoptosis
S. Permpongkosol
,
Jing‐ding Wang
,
+6 authors
A. Okuyama
International Journal of Cancer
2002
Corpus ID: 12775621
Despite the high frequency of prostate cancer, therapeutic options for advanced disease are limited to chemotherapy, radiation or…
Expand
Highly Cited
2000
Highly Cited
2000
Effect of FTY720, a novel immunosuppressant, on adjuvant- and collagen-induced arthritis in rats.
M. Matsuura
,
T. Imayoshi
,
T. Okumoto
International Journal of Immunopharmacology
2000
Corpus ID: 43662769
Highly Cited
1999
Highly Cited
1999
Early induction of apoptosis in androgen‐independent prostate cancer cell line by FTY720 requires caspase‐3 activation
Jing‐ding Wang
,
S. Takahara
,
+6 authors
Seiichi Suzuki
The Prostate
1999
Corpus ID: 43417879
We previously reported that FTY720, a metabolite from Isaria sinclairii, induced some cancer cells to undergo apoptosis, and that…
Expand
Highly Cited
1998
Highly Cited
1998
Immunosuppressive effects of FTY720 alone or in combination with cyclosporine and/or sirolimus.
M. Wang
,
N. Tejpal
,
+4 authors
B. Kahan
Transplantation
1998
Corpus ID: 13024055
BACKGROUND We examined the ability of FTY720, a novel immunosuppressant that prolongs the survival of allografts in experimental…
Expand
Highly Cited
1996
Highly Cited
1996
A new immunosuppressant, FTY720, induces bcl‐2‐associated apoptotic cell death in human lymphocytes
Seiichi Suzuki
,
X-K. Li
,
S. Enosawa
,
T. Shinomiya
Immunology
1996
Corpus ID: 27357734
FTY720 is a unique immunosuppressive drug produced by modification of a metabolite from Isaria sinclairii. In vitro treatment of…
Expand
Highly Cited
1996
Highly Cited
1996
FTY720, a novel immunosuppressant possessing unique mechanisms. III. Synergistic prolongation of canine renal allograft survival in combination with cyclosporine A.
T. Kawaguchi
,
Y. Hoshino
,
+8 authors
Seiichi Suzuki
Transplantation Proceedings
1996
Corpus ID: 34157410
Highly Cited
1996
Highly Cited
1996
FTY720, a novel immunosuppressant possessing unique mechanisms. II. Long-term graft survival induction in rat heterotopic cardiac allografts and synergistic effect in combination with cyclosporine A.
Y. Hoshino
,
C. Suzuki
,
M. Ohtsuki
,
Y. Masubuchi
,
Y. Amano
,
K. Chiba
Transplantation Proceedings
1996
Corpus ID: 22409931
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE